Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study Mayo Clinic News Network
Повышение осведомленности о раке молочной железы: проактивная и улучшенная ранняя диагностика. Vietnam.vn
Atlantic Health gets record $5M gift for cancer research NJBIZ
FORTITUDE-101 and FORTITUDE-102 at ESMO 2026: Bemarituzumab Efficacy by FGFR2 Amplification Status in Gastric and GEJ Cancer Oncodaily
Personalized cancer vaccine cuts risk of melanoma recurrence or death by 42% in trial Anadolu Ajansı
Michelle Mitchell: CRUK Scotland Institute Celebrates 50 Years of Cancer Research and Innovation Oncodaily
An overlooked mechanism in lung cancer tumors may help explain why most patients don't respond to immunotherapy, according to new research led by Olga Anczuków, professor at The Jackson Laboratory for Genomic Medicine in Farmington, Connecticut, and deputy director of the NCI-designated Jackson Laboratory Cancer…
DENALI Trial at ESMO 2026: Azenosertib Shows 15.8-Month Overall Survival in Cyclin E1-Positive Ovarian Cancer Oncodaily
INCB123667 Plus Bevacizumab at ESMO 2026 Shows 48% Response Rate in Recurrent Ovarian Cancer Oncodaily
INCB123667 Plus Bevacizumab at ESMO 2026 Shows 48% Response Rate in Recurrent Ovarian Cancer Oncodaily
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer Targeted Oncology
Genomic Test Predicts Which Prostate Cancer Patients Benefit From Abiraterone Therapy Clinical Lab Products
Presidential Symposium Highlights in Small Cell Lung Cancer The ASCO Post
Of Note in the Oncology Community: September/October 2026 The ASCO Post
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer Oncodaily